 |
Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week
PISCATAWAY, N.J. and SANTA CLARA, Calif., Oct. 8, 2026 /PRNewswire/ — GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript’s wet lab validation and data generation capabilities and NVIDIA’s accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility.
Applications are now open for the GenScript and NVIDIA Life Sciences Startup PitchFest.
Up to six finalists will be selected for a GenScript-hosted pitch event during JPM Week in January before a panel of judges. The winning company will receive GenScript wet lab data credits and Brev credits from NVIDIA to support its development efforts. Applications opened today, and finalists will be confirmed in December.
AI is making therapeutic discovery more expansive than ever, giving scientists new ways to generate hypotheses, identify targets, and design candidates at unprecedented speed. The PitchFest is designed to channel that momentum by connecting emerging AI drug discovery and life science companies with investors, technology leaders, and partners focused on turning computational predictions into biological proof. The competition will feature startups developing technologies such as AI-driven antibody and protein design, as well as technologies that accelerate the design-build-test-learn cycle.
“To harness the true potential of AI in life sciences, we must build an ecosystem where world-class computation meets trusted, scalable biological validation,” said Ray Chen, President of GenScript Life Science Group. “Success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move with confidence from computational promise to therapeutic progress. PitchFest gives digital biology startups integrated support to rapidly test their models, generate evidence, and accelerate breakthrough therapies.”
Through the competition, GenScript will contribute sequence-to-data capabilities and experimental validation expertise, while NVIDIA will provide access to NVIDIA Inception, its free program that helps startups build, scale, and connect across the NVIDIA platform and ecosystem. Together, GenScript and NVIDIA will help selected startups move from promising AI-driven concepts toward stronger biological evidence, investor readiness, and potential partnerships.
Finalists will also be invited to GenScript’s Biotech Global Forum, where they can engage with biotechnology executives, strategic partners, and industry leaders focused on the future of AI-enabled discovery.
Additional details on judging criteria, speakers, and investor participation will be announced in the coming weeks as the program helps AI-driven life science startups generate evidence, build industry relationships, and accelerate their own commercialization journeys.
About GenScript Biotech Corporation
Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners – from academic institutions to industry leaders – to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world’s Top 20 pharma companies. For more information: www.genscript.com.
Media Contacts:
Kate Grusich, GenScript Biotech Corporation
[email protected]
